Statement of Ownership (sc 13g)
May 16 2022 - 6:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
MAINZ BIOMED N.V.
(Name of Issuer)
Ordinary Shares, €0.01 par value
per share
(Title of Class of Securities)
N5436L101
(CUSIP Number)
May 3, 2022
(Date of Event Which Requires Filing
of this Statement)
Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:
* | The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No.
1. |
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Moritz Eidens
|
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ☐
(b) ☐ |
3.
|
SEC USE ONLY
|
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Germany
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH: |
5. |
SOLE VOTING POWER
1,007,615 |
6. |
SHARED VOTING POWER
|
7. |
SOLE DISPOSITIVE POWER
1,007,615 |
8. |
SHARED DISPOSITIVE POWER
|
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,007,615 |
10. |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
|
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.2% |
12. |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN |
Item 1(a).
Name of Issuer:
Mainz BioMed N.V. (the “Issuer”)
Item
1(b). Address of Issuer’s Principal Executive Offices:
Robert Koch Strasse 50, 55129 Mainz,
Germany
Item 2(a).
Names of Persons Filing:
The names of the persons filing this report (collectively, the “Reporting
Persons”) are:
Moritz Eidens
Item 2(b).
Address of Principal Business Office or, if None, Residence:
The address of the principal business
office of each of the Reporting Persons is:
Robert Koch Strasse 50, 55129 Mainz, Germany
Item 2(c).
Citizenship:
Germany
Item 2(d).
Title of Class of Securities:
Ordinary Shares, par value €0.01
per share (“Ordinary Shares”)
Item 2(e).
CUSIP Number:
N5436L101
Item 3. If
this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable.
Item
4. Ownership.
(a) Amount beneficially owned: 1,007,615 Ordinary Shares
(b) Percent of class: 7.2%
(c) Number of shares as to which the person has
| (i) | Sole power to vote or to direct the vote 1,007,615 Ordinary Shares |
| (ii) | Shared power to vote or to direct the vote 0 Ordinary Shares |
| (iii) | Sole power to dispose or to direct the disposition of 1,007,615
Ordinary Shares |
| (iv) | Shared power to dispose or to direct the disposition of 0
Ordinary Shares |
Item 5. Ownership
of Five Percent or Less of a Class.
If this statement is being filed to report the
fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of
securities, check the following ☐.
Item 6. Ownership
of More than Five Percent on Behalf of Another Person.
Not applicable.
Item
7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
or Control Person.
Not applicable.
Item
8. Identification and Classification of Members of the Group.
Not applicable.
Item
9. Notice of Dissolution of Group.
Not applicable.
Item
10. Certification.
By signing below I certify that, to the best of
my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired
and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities
solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of its
knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Date: May 16, 2022
MORITZ EIDENS |
|
|
|
|
By: |
/s/ Moritz Eidens |
|
Name: |
Moritz Eidens |
|
5
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Apr 2023 to Apr 2024